Bristol’s Yervoy Adds Up to 10 Years of Life for Cancer Patients
This article is for subscribers only.
Bristol-Myers Squibb Co.’s skin cancer drug Yervoy extends the lives of patients by as much as 10 years, in the first study to show the treatment’s effect on long-term survival.
An analysis of more than 1,800 patients from 12 trials showed that 22 percent were still alive three years after treatment, and 17 percent survived seven years, after which there were no deaths, according to data to be presented at a cancer conference in Amsterdam today. The longest recorded survival was 9.9 years, researchers led by Stephen Hodi from Boston’s Dana-Farber Cancer Institute said in a statement.